Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P11274

UPID:
BCR_HUMAN

ALTERNATIVE NAMES:
Renal carcinoma antigen NY-REN-26

ALTERNATIVE UPACC:
P11274; P78501; Q12842; Q4LE80; Q6NZI3

BACKGROUND:
Breakpoint cluster region protein, alternatively named Renal carcinoma antigen NY-REN-26, is integral to regulating small GTP-binding proteins. It features a GTPase-activating protein (GAP) domain targeting RAC1, RAC2, and CDC42, and a guanine nucleotide exchange factor (GEF) domain affecting CDC42, RHOA, and RAC1. Its amino terminus exhibits kinase activity, underscoring its multifunctional nature.

THERAPEUTIC SIGNIFICANCE:
Involvement of the Breakpoint cluster region protein in chronic myeloid leukemia, marked by the presence of the Philadelphia chromosome, underscores its therapeutic significance. Leveraging insights into its function offers a promising avenue for developing novel treatments for this and potentially other myeloproliferative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.